Panelists include leaders in the fields of science, medicine and technology: Jack Hidary, Dr. Edward Neilan, Dr. Shoshana Shendelman, Dr. John Greely, Louis ReesePanelists include leaders in the fields of science, medicine and technology: Jack Hidary, Dr. Edward Neilan, Dr. Shoshana Shendelman, Dr. John Greely, Louis Reese

Inaugural Cures Conference to be held on Thursday, February 5, 2026 in NYC

Panelists include leaders in the fields of science, medicine and technology: Jack Hidary, Dr. Edward Neilan, Dr. Shoshana Shendelman, Dr. John Greely, Louis Reese and Nadia Harhen.

NEW YORK, Jan. 21, 2026 /PRNewswire/ — Introducing the inaugural Cures Conference to be held in NYC on Thursday, February 5, 2026. 

The Cures Conference convenes scientists, physicians, pharmaceutical executives, tech leaders, and government officials to leverage their collective expertise—highlighting innovations, advancing understanding, accelerating treatment development, and driving real-world implementation.

Panel discussions will include topics such as:

  • How artificial intelligence can accelerate innovation;
  • How advances in technology can translate to access to medicines for all; and
  • How we can improve health outcomes globally

Noted Panelists:

Jack Hidary  
Jack Hidary is the CEO of SandboxAQ, with a focus on enterprise SaaS solutions at the convergence of AI and Quantum tech.

Dr. Edward Neilan MD, PhD
Dr. Edward “Ed” Neilan is the Chief Medical and Scientific Officer of the National Organization for Rare Disorders (NORD®). Ed is a physician-scientist and rare disease expert.

Dr. Shoshana Shendelman PhD
Dr. Shoshana Shendelman is a scientist and entrepreneur who has founded numerous biotech companies. She is a pioneer in the development of drugs for rare and underserved diseases. Currently she is Vice Chair of the Board of Advisors at Columbia University Medical Center and Columbia University Vagelos College of Physicians and Surgeons. 

Dr. John Greally MD
Dr. John Greally is the Chief of the Division of Genomics, at Albert Einstein College of Medicine; Director, New York Center for Rare Diseases (NYCRD); Director, Center for Epigenomics, Albert Einstein College of Medicine; and Professor of Genetics and Pediatrics, Albert Einstein College of Medicine. Dr. Greally is a specialist in clinical genetics, with an emphasis on rare and congenital diseases. 

Louis Reese
Lou Reese is a co-founder, CEO and member of Board of Directors at United Neuroscience.

Nadia Harhen
Nadia Harhen is the General manager of AI Simulation at SandboxAQ. By combining the versatility of AI with the accuracy of quantum simulation, she is radically shifting the rate and cost of drug, material, and chemical discovery.

The Cures Conference will be held at The Ned, 1170 Broadway, New York, New York.  For more information, visit https://curesconference.com. Please contact Sam Sohaili at sam@dmaunited.com for registration and attendance information.

For Press Inquiries:
nancyc@dmaunited.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inaugural-cures-conference-to-be-held-on-thursday-february-5-2026-in-nyc-302667523.html

SOURCE DMA United

Market Opportunity
John Tsubasa Rivals Logo
John Tsubasa Rivals Price(JOHN)
$0.00708
$0.00708$0.00708
-4.06%
USD
John Tsubasa Rivals (JOHN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Bitcoin ETFs Surge with 20,685 BTC Inflows, Marking Strongest Week

Bitcoin ETFs Surge with 20,685 BTC Inflows, Marking Strongest Week

TLDR Bitcoin ETFs recorded their strongest weekly inflows since July, reaching 20,685 BTC. U.S. Bitcoin ETFs contributed nearly 97% of the total inflows last week. The surge in Bitcoin ETF inflows pushed holdings to a new high of 1.32 million BTC. Fidelity’s FBTC product accounted for 36% of the total inflows, marking an 18-month high. [...] The post Bitcoin ETFs Surge with 20,685 BTC Inflows, Marking Strongest Week appeared first on CoinCentral.
Share
Coincentral2025/09/18 02:30
XAG/USD retreats toward $113.00 on profit-taking pressure

XAG/USD retreats toward $113.00 on profit-taking pressure

The post XAG/USD retreats toward $113.00 on profit-taking pressure appeared on BitcoinEthereumNews.com. Silver price (XAG/USD) halts its seven-day winning streak
Share
BitcoinEthereumNews2026/01/30 10:21
BTC Leverage Builds Near $120K, Big Test Ahead

BTC Leverage Builds Near $120K, Big Test Ahead

The post BTC Leverage Builds Near $120K, Big Test Ahead appeared on BitcoinEthereumNews.com. Key Insights: Heavy leverage builds at $118K–$120K, turning the zone into Bitcoin’s next critical resistance test. Rejection from point of interest with delta divergences suggests cooling momentum after the recent FOMC-driven spike. Support levels at $114K–$115K may attract buyers if BTC fails to break above $120K. BTC Leverage Builds Near $120K, Big Test Ahead Bitcoin was trading around $117,099, with daily volume close to $59.1 billion. The price has seen a marginal 0.01% gain over the past 24 hours and a 2% rise in the past week. Data shared by Killa points to heavy leverage building between $118,000 and $120,000. Heatmap charts back this up, showing dense liquidity bands in that zone. Such clusters of orders often act as magnets for price action, as markets tend to move where liquidity is stacked. Price Action Around the POI Analysis from JoelXBT highlights how Bitcoin tapped into a key point of interest (POI) during the recent FOMC-driven spike. This move coincided with what was called the “zone of max delta pain”, a level where aggressive volume left imbalances in order flow. Source: JoelXBT /X Following the test of this area, BTC faced rejection and began to pull back. Delta indicators revealed extended divergences, with price rising while buyer strength weakened. That mismatch suggests demand failed to keep up with the pace of the rally, leaving room for short-term cooling. Resistance and Support Levels The $118K–$120K range now stands as a major resistance band. A clean move through $120K could force leveraged shorts to cover, potentially driving further upside. On the downside, smaller liquidity clusters are visible near $114K–$115K. If rejection holds at the top, these levels are likely to act as the first supports where buyers may attempt to step in. Market Outlook Bitcoin’s next decisive move will likely form around the…
Share
BitcoinEthereumNews2025/09/18 16:40